Moderate

Asthma-COPD overlap (ACO)

mixed obstruction · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

ACO describes persistent airflow limitation with features of both asthma (variability, eosinophilia, atopy) and COPD (smoking/exposure, incomplete reversibility). It is a pragmatic label, not a single disease, and carries higher exacerbation and symptom burden than either alone.

Red flags

  • Frequent exacerbations despite triple therapy
  • Rapid FEV1 decline
  • Hypoxaemia / cor pulmonale
  • Weight loss or haemoptysis prompting malignancy work-up

Assessment

Differential diagnosis

  • Asthma with fixed airflow obstruction
  • COPD with eosinophilia/bronchodilator reversibility
  • Bronchiectasis
  • Chronic heart failure
  • Combined pulmonary fibrosis and emphysema

Investigations

  • Post-bronchodilator spirometry (FEV1/FVC <0.70 with significant reversibility)
  • Blood eosinophil count
  • FeNO
  • Total/specific IgE and atopy assessment
  • Chest X-ray / HRCT to assess emphysema and exclude bronchiectasis
  • Lung volumes and DLCO; alpha-1 antitrypsin if emphysema and limited smoking

Management

  • Confirm persistent airflow obstruction with incomplete reversibility
  • Document both asthma (variability, eosinophils, atopy) and COPD (smoking/biomass, structural damage) features
  • Quantify exacerbation history and symptom burden (CAT/mMRC)
  • Start ICS-containing therapy early (never LABA or LAMA alone) because of the asthma component
  • Build to triple therapy ICS-LABA-LAMA where symptoms/exacerbations persist
  • Address smoking cessation aggressively and ensure vaccinations
  • Assess eosinophils to guide ICS intensity and exacerbation risk
  • Enrol in pulmonary rehabilitation
  • Treat comorbidities and manage exacerbations as for the dominant phenotype
  • Review response and consider specialist phenotyping if poorly controlled

Drugs & doses

ICS-LABA e.g. budesonide-formoterol 200/6 mcg 2 puffs twice daily
Triple therapy e.g. fluticasone furoate-umeclidinium-vilanterol 92/55/22 mcg once daily
Tiotropium 2.5 mcg 2 puffs once daily (LAMA)
Varenicline 1 mg PO twice daily for smoking cessation

Disposition

General respiratory clinic; pulmonary rehab referral; specialist review if refractory.

Complications & pitfalls

  • Accelerated lung-function decline
  • Frequent exacerbations and hospitalisation
  • Pneumonia risk from inhaled steroids
  • Progression to chronic respiratory failure

Exam pearls

  • Never treat the airflow obstruction as pure COPD with bronchodilator-only therapy if asthma features exist — ICS is key
  • Higher eosinophils predict ICS responsiveness and exacerbation risk
  • ACO patients have worse quality of life than asthma or COPD alone
  • Always exclude bronchiectasis and heart failure as contributors

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.